← Eichor
Study identifier: NCT06344442 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

Condition: Acute Kidney Injury Post Liver Transplantation  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhasePhase 3
Planned participants304
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality. Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension, binds to AVPR1a to promote vasoconstriction. Furthermore, it may have nephroprotective effects with a preferential vasoconstriction of the post-glomerular arteriole resulting in increased glomerular filtration The hypothesis of the present work is that low-dose arginine-vasopressin supplementation reduce posttransplant AKI in liver transplantation.

This description comes directly from the study's public registry record.

Talk to the study team

Jacques DURANTEAU, Pr  ·  01 45 21 34 41  ·  jacques.duranteau@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (1)

URC Lariboisière-Fernand Widal-saint LouisParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06344442